{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:04:11Z","timestamp":1787069051198,"version":"build-2736575974"},"reference-count":23,"publisher":"Informa UK Limited","issue":"12","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Biological Therapy"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1080\/14712598.2024.2425343","type":"journal-article","created":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T06:28:38Z","timestamp":1730701718000},"page":"1329-1334","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":4,"title":["Will zilebesiran, an RNA interference therapy, be effective, safe, and improve the treatment of hypertension?"],"prefix":"10.1080","volume":"24","author":[{"given":"Sheila A.","family":"Doggrell","sequence":"first","affiliation":[{"name":"School of Pharmacy and Medical Sciences, Gold Coast Campus, Griffith University, Gold Coast, Queensland, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2024,11,6]]},"reference":[{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.0728"},{"key":"e_1_3_3_4_1","unstructured":"Clinicaltrials.gov. A study to evaluate efficacy and safety of ALN-AGT01 in patients with mild to-moderate hypertension (KARDIA-1). [cited 2024 Mar 4]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04936035"},{"key":"e_1_3_3_5_1","unstructured":"World Health Organization. Hypertension. [cited 2024 Mar 11]. Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hypertension"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-27377-2"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.118.313220"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41371-018-0149-8"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.122.18731"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacbts.2021.04.004"},{"key":"e_1_3_3_11_1","unstructured":"Clinicaltrials.gov. IONIS-AGT-LRx https: \/\/clinicaltrials.Gov\/search?intr=IONIS-AGT-LRx. [cited 2024 Mar 15]."},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2208391"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2310167"},{"key":"e_1_3_3_14_1","first-page":"1439","article-title":"Zilebesiran for hypertension","volume":"389","author":"Desai AS","year":"2023","unstructured":"Desai AS, Sweetser MT, Bakris L. Zilebesiran for hypertension. N Engl J Med. 2023;389:1439\u20131440.","journal-title":"N Engl J Med"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2310167"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2310167"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.124.22878"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe2303534"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.4136"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2024.03.021"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.032031"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13154543"},{"key":"e_1_3_3_23_1","unstructured":"Clinicaltrials.gov. Zilebesiran as add-on therapy in patients with hypertension not adequately controlled by a standard of care antihypertensive medication (KARDIA-2). [cited 2024 Mar 15]. p. KARDIA\u20132. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05103332?intr=zilebesiran&rank=2"},{"key":"e_1_3_3_24_1","unstructured":"Clinicaltrials.gov. Zilebesiran as add-on therapy in patients with high cardiovascular risk and hypertension not adequately controlled by standard of care antihypertensive medications (KARDIA-3). [cited 2024 Mar 15]. p. KARDIA\u20133. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06272487?intr=zilebesiran&rank=1"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40256-022-00534-9"}],"container-title":["Expert Opinion on Biological Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14712598.2024.2425343","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T11:42:28Z","timestamp":1733312548000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14712598.2024.2425343"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,6]]},"references-count":23,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["10.1080\/14712598.2024.2425343"],"URL":"https:\/\/doi.org\/10.1080\/14712598.2024.2425343","relation":{},"ISSN":["1471-2598","1744-7682"],"issn-type":[{"value":"1471-2598","type":"print"},{"value":"1744-7682","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,6]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-04-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-31","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}